Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: Quantitation and virus characterization

AIDS Research and Human Retroviruses

Volumn 17, Issue 7, 2001, Pages 577-586

  Dyrhol Riise, A M ^a   Voltersvik, P ^a   Berg, O G ^a   Olofsson, J ^b   Kleivbo, S ^a   Asjo B ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LATENT PERIOD; LYMPHOCYTE COUNT; LYMPHOID TISSUE; PRIORITY JOURNAL; PROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TONSIL; VIREMIA; VIRUS CHARACTERIZATION; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TITRATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; LONGITUDINAL STUDIES; LYMPHOID TISSUE; PHENOTYPE; PROVIRUSES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD; VIREMIA; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0034938543     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201300119671     Document Type: Article

References (52)

1. Lymphoid organs function as major reservoirs for human immunodeficiency virus
2. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA
3. Quantitative image analysis of HIV-1 infection in lymphoid tissue
4. High viral burden in lymph nodes during early stages of HIV-1 infection
5. Correlates of latent and productive HIV type-1 infection in tonsillar CD4(+) T cells
6. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
7. Altered follicular dendritic cells and virus-like particles in AIDS and AIDS-related lymphadenopathy
8. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection
9. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA
10. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
11. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1
12. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS
13. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains
14. HIV-1 dynamics in vivo: Viron clearance rate, infected cell life-span, and viral generation time
15. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
16. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue
17. Human immunodeficiency virus type 1 dynamics in different lymphoid tissue compartments
18. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
19. Quantification of HIV-1 viral load in lymphoid and blood cells: Assessment during four-drug combination therapy
20. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
21. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
22. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection
23. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
24. Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy
25. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
26. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection
27. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
28. Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy
29. Reduced CD4 cell counts in blood do not reflect CD4 cell depletion in tonsillar tissue in asymptomatic HIV-1 infection
30. Few infected CD4+ T cells but a high proportion of replication-competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection
31. Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics
32. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
33. Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers
34. Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues
35. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
36. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients
37. Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors
38. The CLUSTAL_X Windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools
39. A new classification for HIV-1
40. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
41. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine
42. Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma
43. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
44. Population biology of HIV-1 infection: Viral and CD4+ T cell demographics and dynamics in lymphatic tissues
45. Naturally occurring HIV-1 isolates with differences in replicative capacity are distinguished by in situ hybridization of infected cells
46. Characterization of long-term survivors of human immunodeficiency virus type 1 infection
47. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue
48. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine
49. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
50. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection
51. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
52. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir